A synthetic, long-acting alternative to human insulin is insulin glargine. It functions by taking the place of the body’s natural insulin and assisting in the transfer of blood sugar into other bodily tissues where it is converted to energy. Insulin glargine is used, like other forms of insulin, to maintain blood sugar levels that are close to normal. Adults with type 1 diabetes, children with type 1 diabetes, and adults with type 2 diabetes may be treated with insulin glargine, according to the FDA (Food and Drug Administration). A basal insulin level is provided throughout the day by this long-acting insulin, which is administered once daily. It is a reformulated version of basal or long-acting insulin used to manage hyperglycemia in people with diabetes mellitus. Consequently, there is a rise in the demand for insulin.
Request For Sample Report (Including Full TOC, Table & Figures) @
https://www.coherentmarketinsights.com/insight/request-sample/5231
Market Drivers:
Over the course of the forecast period, more clinical studies and more R&D are anticipated to fuel the expansion of the worldwide insulin glargine market. For instance, Lannett has fulfilled its commitment to begin a pivotal clinical trial for its proposed interchangeable biosimilar competitor to Lantus by the end of March 2022 as it plans to file for and launch its insulin glargine product in the United States in 2023. Lannett has partnered with HEC Group on this project. The Lannett biosimilar’s reference biologic, Lantus, has also received permission for usage in the United States.
Market Opportunities:
Because diabetes is becoming more common worldwide, the demand for insulin glargine is likely to rise, providing profitable prospects for market participants. For instance, more than 537 million individuals (20-79 years old) have diabetes, according to the International Diabetes Federation (IDF). Furthermore, it is anticipated that 643 million people would have diabetes by 2030 and 783 million by 2045. Furthermore, type 2 diabetes is more likely to occur in 541 million persons. As a result, it is anticipated that demand for insulin glargine would rise globally.
Due to their weakened immune systems, persons with diabetes are more likely than those without concomitant conditions to develop significant consequences from COVID-19. Higher fatality rates and longer hospital admissions have been associated with diabetes and poorly controlled glucose levels in COVID-19 patients. According to several research, people who get COVID-19 may be more likely to develop diabetes.
Key Takeaways:
The market for insulin glargine was valued at US$6,153.5 million in 2021, and it is anticipated that it would grow at a CAGR of 0.2% from 2022 to 2028 to reach US$6,257.7 million.
Type Lantus held a leading position in the worldwide market for insulin glargine in 2021, accounting for 42.7% of the market’s value share. Increasing approval and the introduction of new products are anticipated to fuel segment expansion throughout the forecast period.
Market Trends
The global market for insulin glargine is anticipated to develop as public knowledge of managing diabetes rises. The first step in controlling and preventing diabetes is understanding it. To assist people with diabetes and those who provide care for them in making educated decisions about their illness, the International Diabetes Federation’s School of Diabetes has created a new online learning environment.
The global market for insulin glargine is anticipated to increase rapidly as a result of frequent approvals and launches of innovative medicines. For instance, Novo Nordisk’s Rybelsus (oral semaglutide) was given marketing authorization by the European Commission in April 2020 to treat persons with type II diabetes that is not well managed. The United Kingdom and all other members of the European Union are covered by the marketing authorization.
Download PDF Brochure with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-pdf/5231
Competitive Landscape
The market for insulin glargine is dominated by companies like Julphar, Biocon, Eli Lilly, Sanofi Aventis, and Novo Nordisk AS, among others.
Recent Developments
Tirzepatide produced improved A1C and body weight reductions from baseline in persons with type-2 diabetes and elevated cardiovascular risk, according to a recent announcement by Eli Lilly & Company in November 2021.
The introduction of Semglee (insulin glargine injection) in vial and pre-filled pen presentations in the United States, authorised to treat people with diabetes, was announced by Biocon Biologics India Ltd. and Mylan N.V. in August 2020.
Reasons to buy this Insulin Glargine Market Report
☑ It attempts an analysis of the competing scenario.
☑ The current and exceptional product revenue market.
☑ An in-depth data on the regional investigation and competitive landscape structure.
☑ It benefits in creating an awareness of the important key product segments.
☑ The marketing strategies, opportunities, and development factors are explained.
☑ Insulin Glargine market size estimation and recent advancements in the industry are explained.
Buy This Complete Business Report @ https://www.coherentmarketinsights.com/insight/buy-now/5231
Table of Content
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Geography
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Increasing prevalence of diabetes worldwide
- High cost of insulin glargine
- Increase in awareness about diabetes management
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER’s Analysis
- Merger and Acquisition Scenario
- Market Dynamics
- Global Insulin Glargine Market– Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
- Global Insulin Glargine Market, By Type, 2017-2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 – 2028
- Segment Trends
- Insulin Glargine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
- Introduction
- Global Insulin Glargine Market, By Geography, 2017-2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 – 2028
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
- Middle East and Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
- Rest of World
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
- Introduction
- Competitive Landscape
- Julphar
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Biocon
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi Aventis
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novo Nordisk AS
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Analyst Views
- Julphar
- Section
- Research Methodology
- About us
Related Reports
Injectable drugs market analysis
Human insulin drug market analysis
Pediatric nutrition market analysis
Generic sterile injectable market analysis
About Coherent Market Insights
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact us:
Mr. Shah
Coherent Market Insights
533 Airport Boulevard, Suite 400,
Burlingame, CA 94010, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com